KJ C1807
Alternative Names: CT-048; KJ-C1807Latest Information Update: 09 Jun 2023
At a glance
- Originator CARsgen
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Gastric cancer; Pancreatic cancer
Most Recent Events
- 04 Aug 2022 Phase-I clinical trials in Gastric cancer (In the elderly, In adults, Late-stage disease, Second-line therapy or greater) in China (Parenteral) (NCT05393986)
- 04 Aug 2022 Phase-I clinical trials in Pancreatic cancer (In the elderly, In adults, Late-stage disease, Second-line therapy or greater) in China (Parenteral) (NCT05393986)
- 27 May 2022 CARsgen plans a phase I trial for Gastric cancer and Pancreatic cancer (Late-stage disease; First-line therapy) (NCT05393986)